To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
Phase
1/2Span
292 weeksSponsor
Incyte Biosciences Japan GKTachikawa
Recruiting
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Phase
3Span
160 weeksSponsor
Samsung Bioepis Co., Ltd.Tachikawa
Recruiting
1-2 of 2